Table 1.
Demographic and Clinical Characteristics of Patients in the Study Stratified by Presence of Absence of Antigenemia Above the Clinic Threshold of 3.0 pg/mL
| Characteristics | Patients With Antigenemia (N = 30) |
Patients Without Antigenemia (N = 24) |
|---|---|---|
| Female | 18 (60%) | 11 (45.8%) |
| Age, years; median (range) | 56 (21–79) | 54.5 (22–85) |
| Immunocompromised | 20 (66.7%) | 9 (37.5%) |
| SARS-CoV-2 Vaccine Documented | 11 (36.7%) | 10 (41.7%) |
| 2 doses | 7 (63.6%) | 5 (50%) |
| 3 doses | 4 (36.4%) | 3 (30%) |
| 4 doses | 0 (0%) | 2 (20%) |
| Prior positive COVID test (healthcare system) | 6 (20%) | 5 (20.8%) |
| Prior positive COVID test (reported) | 11 (36.7%) | 3 (12.5%) |
| Hours between blood and NP specimens; mean (range) | 0.2 (−5.4 to 11.2) | −0.1 (−6.7 to 4.2) |
| Asymptomatic | 4 (13.3%) | 6 (25%) |
| Any Reported COVID-19 Symptoms | 26 (86.7%) | 18 (75%) |
| Active at time of sampling | 24 (92.3%) | 18 (100%) |
| Days since COVID-19 symptom onset; median (range) | 8 (0–50) | 7 (0–62) |
| Encounter primarily for COVID-19 | 18 (60%) | 11 (45.8%) |
| Chest X-Ray Obtained | 25 (83.3%) | 24 (100%) |
| Abnormal | 18 (72%) | 6 (25%) |
| WHO Ordinal Scale | ||
| 4 | 22 (73.3%) | 15 (62.5%) |
| 5 | 4 (13.3%) | 6 (25%) |
| 6 | 3 (10%) | 0 (0%) |
| 7 | 1 (3.3%) | 3 (12.5%) |
Abbreviations: COVID-19, coronavirus disease 2019; NP, nasopharyngeal; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health Organization.